top of page

The Science Behind the News: Ascidian Therapeutics' IND is cleared for an RNA exon editing program against Stargardt disease

Ascidian Interim President & CEO Mike Ehlers explains the scientific concept of RNA exon editing, how Stargardt as an indication is a natural fit as a proof of concept, and why he believes FDA clearance of the IND without ex-U.S. clinical data is meaningful.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page